Perioperative treatment of oesophageal, oesophago-gastric and gastric adenocarcinoma: new standards of care and controversies Editorial article
Article Sidebar
Main Article Content
Abstract
Oesophageal, gastroesophageal and gastric cancers represent important diagnostic and therapeutic challenge. Even after radical surgical procedure (R0) 5-year survival remains unsatisfactory. It is assumed that perioperative chemo/radiotherapy eliminates local and distant micrometastases. This year (2012) a consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer was published as a result of the first EORTC St. Gallen International Expert Consensus. Despite a significant progress in the perioperative treatment of locally advanced cancers of upper digestive tract, results of several ongoing clinical trials that may further optimize systemic treatment of these malignancies are eagerly awaited.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
2. Gunderson L.L.: Gastric cancer – patterns of relapse after surgical resection. Semin. Radiat. Oncol. 2002; 12(2): 150-61.
3. D’Angelica M., Gonen M., Brennan M.F. et al.: Patterns of initial recurrence in completely resected gastric adenocarcinoma. Ann. Surg. 2004; 240(5): 808-16.
4. Siewert J.R., Stein H.J.: Classification of adenocarcinoma of the oesophagogastric junction. Br. J. Surg. 1998; 85: 1457-9.
5. Walsh T.N., Noonan N., Hollywood D. et al.: A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N. Engl. J. Med. 1999; 335: 462-467.
6. Gaast A., van Hagen P., Hulshof M. et al.: Effect of preoperative concurrent chemoradiotherapy on survival of patients with respectable esophageal or esophagogastric junction cancer: Results from multicenter randomized phase III study. J. Clin. Oncol. 2010; 28(15): abstr. 4004.
7. Hartgrink H.H., van de Velde C.J., Putter H. et al.: Neo-adjuvant chemotherapy for operable gastric cancer: long term results of the Dutch randomised FAMTX trial. Eur. J. Surg. Oncol. 2004; 30(6): 643-9.
8. Cunningham D., Allum W.H., Stenning S.P. et al.: Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer. N. Engl. J. Med. 2006; 355: 11-20.
9. Boige V., Pignon J., Saint-Aubert B. et al.: Final results of randomized trial comparing preoperative 5 fluorouracil(F)/cisplatin(C) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORDO7-FFCD 9703 trial. J. Clin. Oncol. 2007; 25: 18s, abstr. 4510.
10. Sasako M., Sakuramoto S., Katai H. et al.: Five-Year Outcomes of a Randomized Phase III Trial Comparing Adjuvant Chemotherapy With S-1 Versus Surgery Alone in Stage II or III Gastric Cancer. J. Clin. Oncol. 2011; 29(33): 4387-4393.
11. Bang Y.J., Kim Y.W., Yang H.K. et al.: Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 2012; 379(9813): 315-321.
12. Macdonald J.S., Smalley S.R., Benedetti J. et al.: Chemoradiotherapy after Surgery Compared with Surgery Alone for Adenocarcinoma of the Stomach or Gastroesophageal Junction. N. Engl. J. Med. 2001; 345(10): 725-730.
13. Smalley S.R., Benedetti J.K., Haller D.G. et al.: Updated Analysis of SWOG-Directed Intergroup Study 0116: A Phase III Trial of Adjuvant Radiochemotherapy Versus Observation After Curative Gastric Cancer Resection. J. Clin. Oncol. 2012; 30(19): 2327-2333.
14. Lee J., Lim do H., Kim S. et al.: Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J. Clin. Oncol. 2012; 30(3): 268-73.
15. Dikken J.L., van Sandick J.W., Swellengrebel H.A.M. et al.: Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer (CRITICS). Online: http://www.biomedcentral.com/1471-2407/11/329.
16. Lutz M.P., Zalcberg J.R., Ducreux M. et al.: Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer – Differential treatment strategies for subtypes of early gastroesophageal cancer. Eur. J. Cancer 2012; 48(16): 2941-53.